Science· 2020Q1
Cytokine release syndrome in severe COVID-19
- 2,040citations
- Q1SCImago
- 2020year
Short summary
Lessons from treating arthritis and cancer with cell therapy suggest a potential therapeutic approach for severe COVID-19.
AI-generated from the title and abstract; the full text is not read.
Key points
- Severe COVID-19 involves a dangerous inflammatory response known as cytokine release syndrome (CRS).
- CRS is a known complication in arthritis and cancer patients treated with cell therapy.
- Therapeutic strategies used for CRS in arthritis and cancer may be applicable to severe COVID-19.
AI-generated from the title and abstract; the full text is not read.
Abstract
Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease
The authors' abstract, as published at the source. Science, 2020 · DOI ↗
TakeawaysPremium
Ask the paperFree account
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Medicine)
NeurologyMedicine